Patents Represented by Attorney Edwin P. Ching

Find this attorney in the Justia Lawyer Directory

  • Mammalian thymokine having leukocyte chemotactic activity, and fragments thereof
    Patent number: 5877285
    Abstract: Nucleic acids encoding a thymokine from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 2, 1999
    Assignee: Schering Corporation
    Inventors: Gregory S. Kelner, Jacqueline L. Kennedy, Albert Zlotnik
  • Antibodies which specifically bind mammalian receptors for interleukin-10 (IL-10)
    Patent number: 5863796
    Abstract: Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 26, 1999
    Assignee: Schering Corporation
    Inventors: Kevin W. Moore, Ying Liu, Alice Suk-Yue Ho, Di-Hwei Hsu, J. Fernando Bazan, Jimmy C. Tan, Chuan-Chu Chou
  • Purified mammalian nucleobase permeases; nucleic acids; antibodies
    Patent number: 5858707
    Abstract: Nucleobase permeases from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids hybridizing to or encoding such proteins. Methods of making and using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: January 12, 1999
    Assignee: Schering Corporation
    Inventors: M. Jorge Guimaraes, J. Fernando Bazan, Terrill K. McClanahan, Albert Zlotnik
  • Method of preparing polypeptide binding compositions derived from immunoglobulin variable regions
    Patent number: 5851801
    Abstract: Proteinaceous binding compositions are prepared employing hybrid DNA technology, where the variable region polypeptides of immunoglobulins are substantially reproduced to provide relatively small protein molecules having binding specificity and lacking the undesirable aspects of the heavy regions of immunoglobulins. The compositions find a wide range of use, particularly for physiological purposes for diagnosis and therapy. The binding compositions may be modified by labeling with radioisotopes, fluorescers, and toxins for specific applications in diagnosis or therapy.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 22, 1998
    Assignee: Schering Corporation
    Inventors: Kevin W. Moore, Alejandro Zaffaroni
  • Hybrid DNA prepared binding composition
    Patent number: 5840545
    Abstract: Proteinaceous binding compositions are prepared employing hybrid DNA technology, where the variable region polypeptides of immunoglobulins are substantially reproduced to provide relatively small protein molecules having binding specificity and lacking the undesirable aspects of the heavy regions of immunoglobulins. The compositions find a wide range of use, particularly for physiological purposes for diagnosis and therapy. The binding compositions may be modified by labeling with radioisotopes, fluorescers, and toxins for specific applications in diagnosis or therapy.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 24, 1998
    Assignee: Schering Corporation
    Inventors: Kevin W. Moore, Alejandro Zaffaroni
  • Use of an interleukin-10 antagonist to treat a B cell mediated autoimmune disorder
    Patent number: 5837232
    Abstract: A method is provided for toting a B cell mediated autoimmune disorder comprising administering an effective amount of an interleukin-10 antagonist.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: Schering Corporation
    Inventors: Rene De Waal Malefyt, Maureen Howard, Di-Hwei Hsu, Hiroshi Ishida, Anne O'Garra, Hergen Spits, Albert Zlotnik
  • Use of interleukin-10 analogs for antagonists to treat endotoxin- or superantigen-induced toxicity
    Patent number: 5837293
    Abstract: A method is provided for reducing an inflammatory response in a mammal comprising administering to a mammal at risk of developing or afflicted with an inflammatory response characterized by substantially elevated levels of IL-1.alpha., IL-1.beta., IL-6, IL-8 and TNF.alpha., an amount of IL-10 effective to substantially lower the levels of such cytokines.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: Schering Corporation
    Inventors: Rene De Waal Malefyt, Maureen Howard, Di-Hwei Hsu, Hiroshi Ishida, Anne O'Garra, Hergen Spits, Albert Zlotnik
  • Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
    Patent number: 5833976
    Abstract: A method is provided for treating septic shock or toxic shock that comprises administering an effective amount of interleukin-10.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: November 10, 1998
    Assignee: Schering Corporation
    Inventors: Rene de Waal Malefyt, Maureen Howard, Di-Hwei Hsu, Hiroshi Ishida, Anne O'Garra, Hergen Spits, Albert Zlotnik
  • Nucleic acids encoding kp43 protein and antigenic fragments thereof
    Patent number: 5811284
    Abstract: The invention provides nucleic acids and polypeptides encoding an NK cell surface antigen from a mammal, as well as antibodies that specifically bind the NK cell surface antigen. Methods of using the nucleic acids, polypeptides, and antibodies are provided, including diagnostic kits comprising one or more of these reagents.
    Type: Grant
    Filed: May 20, 1996
    Date of Patent: September 22, 1998
    Assignees: Schering Corporation, Jose Aramburu Beltran, Miguel Lopez-Botet
    Inventors: Chiwen Chang, Jose Aramburu Beltran, Miguel Lopez-Botet, Joseph H. Phillips, Jr., Lewis L. Lanier
  • Mammalian receptors for interleukin-10 (IL-10)
    Patent number: 5789192
    Abstract: Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.
    Type: Grant
    Filed: August 23, 1993
    Date of Patent: August 4, 1998
    Assignee: Schering Corporation
    Inventors: Kevin W. Moore, Ying Liu, Alice Suk-Yue Ho, Di-Hwei Hsu, J. Fernando Bazan, Jimmy C. Tan, Chuan-Chu Chou
  • Mammalian thymokine genes
    Patent number: 5786210
    Abstract: Nucleic acids encoding a thymokine from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: July 28, 1998
    Assignee: Schering Corporation
    Inventors: Gregory S. Kelner, Jacqueline L. Kennedy, Albert Zlotnik
  • Use of interleukin-10 in adoptive immunotherapy of cancer
    Patent number: 5776451
    Abstract: A method is provided for using interleukin-10 in adoptive immunotherapy of cancer. A population of tumor-infiltrating lymphocytes (TILs) are expanded in culture in the presence of interleukin-2 (IL-2) and interleukin-10 (IL-10). After administration of the TILs to a patient, effective amounts of both IL-2 and IL-10 are administered to enhance the tumor cell cytoxicity of the TILs and to reduce side effects caused by IL-2-induced cytokine production in the TILs and other cells of the patient.
    Type: Grant
    Filed: July 5, 1994
    Date of Patent: July 7, 1998
    Assignee: Schering Corporation
    Inventors: Di-Hwei Hsu, Kevin W. Moore, Hergen Spits
  • Antibodies to mammalian NK antigens and uses
    Patent number: 5770387
    Abstract: Antibodies which specifically bind to an NK cell surface antigen from a mammal, reagents related thereto, including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: June 23, 1998
    Assignees: Schering Corporation, The Board of Trustees of The Leland Stanford Junior University
    Inventors: Virginia M. Litwin, Jennifer E. Gumperz, Peter R. Parham, Joseph H. Phillips, Jr., Lewis L. Lanier
  • BCRF1 proteins as inhibitors of interferon-.gamma.
    Patent number: 5736390
    Abstract: BCRF1 proteins are provided for treating conditions associated with excessive production of IFN-.gamma.. Also provided are expression vectors for producing BCRF1 proteins. Compositions of the invention are useful in treating a variety of disorders, including allergy, psoriasis, tissue rejection, and MHC-linked autoimmune diseases.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 7, 1998
    Assignee: Schering Corporation
    Inventors: Kevin W. Moore, Robert A. Kastelein
  • Mammalian interleukin-10 (IL-10) super-activating receptors; and variants
    Patent number: 5716804
    Abstract: Amino acid sequence and nucleic acid encoding various functional variants of the IL-10 receptors. Uses of the receptor gene and polypeptides are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: February 10, 1998
    Assignee: Schering Corporation
    Inventors: Kevin W. Moore, Sherry Wei, Alice Suk-Yue Ho
  • Human GM-CSF receptor component
    Patent number: 5705611
    Abstract: Nucleic acids encoding the .beta.-chain of the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, as well as the .beta.-chain itself, are provided. The .beta.-chain may be expressed with the .alpha.-chain in cellular hosts to form compositions useful in screening agonists and antagonists of human GM-CSF.
    Type: Grant
    Filed: January 7, 1993
    Date of Patent: January 6, 1998
    Assignee: Schering Corporation
    Inventors: Kazuhiro Hayashida, Toshio Kitamura, Atsushi Miyajima
  • Human interleukin immunopurification processes
    Patent number: 5700915
    Abstract: Monoclonal antibodies are provided which are specific for human interleukin-4. Kits and methods are also provided for detecting, measuring and immunopurifying human interleukin-4, and for blocking the biological activity of human interleukin-4.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: December 23, 1997
    Assignee: Schering Corporations
    Inventors: John S. Abrams, Isabelle Chretien, Frank D. Lee, Michael K. Pearce
  • Muteins of mammalian cytokine interleukin-13
    Patent number: 5696234
    Abstract: Methods for screening for partial agonists and for antagonists of mammalian cytokines. Particular positions of natural cytokines are identified as critical in providing these receptor mediated properties. Specific embodiments demonstrate properties of variations at these positions.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: December 9, 1997
    Assignee: Schering Corporation
    Inventors: Sandra M. Zurawski, Gerard Zurawski
  • Binding compositions for mammalian T cell antigens and related reagents
    Patent number: 5686257
    Abstract: T cell surface antigens from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigens. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: November 11, 1997
    Assignee: Schering Corporation
    Inventors: Jacqueline Kennedy, J. Fernando Bazan, Albert Zlotnik
  • Method of reducing immunoglobulin E responses
    Patent number: 5676940
    Abstract: A method of reducing immunoglobulin E responses associated with certain immune disorders is provided. The method comprises administering an effective amount of an antagonist to human interleukin-4. Preferably, the antagonist is a blocking monoclonal antibody specific for human interleukin-4, or a fragment or binding composition derived therefrom.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: October 14, 1997
    Assignee: Schering Corporation
    Inventors: Robert L. Coffman, Jan Egbert de Vries